RNA vs BMRN vs KO vs JPM vs RARE

For growth investors, Atrium Therapeutics, Inc.

(RNA) is the stronger pick with 70. 9% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 9x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate BioMarin Pharmaceutical Inc. (BMRN) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 15. 9x versus BioMarin Pharmaceutical Inc. at 30. 9x. On forward P/E, BioMarin Pharmaceutical Inc. is actually cheaper at 11. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus The Coca-Cola Company's 2. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +120. 7%, compared to -74. 6% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: JPM returned +475. 6% versus RARE's -59. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Ultragenyx Pharmaceutical Inc. 's 1. 43β — meaning RARE is approximately -816% more volatile than KO relative to the S&P 500. On balance sheet safety, Atrium Therapeutics, Inc. (RNA) carries a lower debt/equity ratio of 2% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Atrium Therapeutics, Inc.

(RNA) is pulling ahead at 70. 9% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -55. 0% for Atrium Therapeutics, Inc.. Over a 3-year CAGR, RNA leads at 26. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -411. 9% for Atrium Therapeutics, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -412. 6% for RNA. At the gross margin level — before operating expenses — RNA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus The Coca-Cola Company's 2. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, BioMarin Pharmaceutical Inc. (BMRN) trades at 11. 3x forward P/E versus 24. 7x for The Coca-Cola Company — 13. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RNA: 96. 1% to $25. 00.

In this comparison, KO (2.

5% yield), JPM (1. 9% yield) pay a dividend. RNA, BMRN, RARE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +118. 2% 10Y return). Both have compounded well over 10 years (KO: +118. 2%, RARE: -59. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RNA (Healthcare) and BMRN (Healthcare) and KO (Consumer Defensive) and JPM (Financial Services) and RARE (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RNA is a small-cap high-growth stock; BMRN is a mid-cap quality compounder stock; KO is a large-cap quality compounder stock; JPM is a large-cap deep-value stock; RARE is a small-cap high-growth stock. KO, JPM pay a dividend while RNA, BMRN, RARE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.